5AM Ventures

5AM Ventures is a leading life science venture capital firm focused on funding and building next-generation life sciences companies. They primarily invest in early-stage private therapeutic companies, with an emphasis on Series A, and also invest in small and mid-cap public and later-stage private biotech and life science companies.

Offices: San Francisco (United States), Boston (United States)

Investment Stages: Seed, Series A, Series B

Markets: Biopharmaceuticals, drug delivery technologies, life science instruments

Founded Year: 2002

Investor Type: Venture Capital

Portfolio Companies: Achaogen (AKAO), Akouos (AKUS), Alexza (ALXA), Ambrx, Aprea (APRE), Artiva Biotherapeutics (ARTV), Arvinas (ARVN), Audentes, Bellerophon (BLPH), Bird Rock Bio, Cabaletta Bio (CABA), Calibrium, Camp4 (CAMP), Cellular Research, Ceterix, Chrono, Cidara (CDTX), CinCor (CINC), Crinetics (CRNX), Dianthus Therapeutics (DNTH), DVS, Enliven Therapeutics (ELVN), Ensoma, Entrada (TRDA), Envoy, Epirus (EPRS), Escient Pharmaceuticals, Expansion Therapeutics, Flexion (FLXN), GlycoEra, Halio, Inc., Homology Medicines, Inc. (FIXX), Ideaya Biosciences, Igenica, Ikaria, Ilypsa, Impel Neuropharma (IMPL), Incline, Inipharm, KaloBios (KBIO), Karius, Kinaset Therapeutics, Latigo, Lifordi, Magnetic Insight, Marcadia, Miikana, Millendo, nChroma Bio, Neurogastrx, Nido Bio, NodThera, Nouscom, Novira, Panomics, Pear (PEAR), Pearl, PhaseRx (PZRX), Portal, Precede Bio, PNI, Pulmatrix (PULM), Purigen, Radionetics, Rallybio (RLYB), RareCyte, Relypsa (RLYP), Rennovia, Scientist.com, scPharmaceuticals (SCPH), Semprus, Skye (SKYE), Synosia, TMRW, VBI Vaccines, Viveve (VIVE), Vor Biopharma (VOR), Wildcat

Website: https://5amventures.com

Team Page: https://5amventures.com/team/

Portfolio Link: https://5amventures.com/portfolio/

LinkedIn: https://www.linkedin.com/company/5amventures

Twitter: https://twitter.com/5amventures

Instagram:

Crunchbase: https://www.crunchbase.com/organization/5am-ventures

Pitchbook: https://pitchbook.com/profiles/investor/11104-03


Leave a Comment